日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模式肿瘤非特异性ctDNA分析用于卵巢癌微小残留病灶检测和风险分层：MITO16a/MaNGO-OV2试验结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106087
Paracchini, L; Velle, A; Di Gennaro, P; Mannarino, L; Ancona, L; Lorusso, D; Cecere, S C; Colombo, N; Beltrame, L; Fagotti, A; Tasca, G; Piemontese, M; Arenare, L; Califano, D; Galdiero, F; Zadro, R; Chiodini, P; Perrone, F; Biagioli, E; D'Incalci, M; Romualdi, C; Pignata, S; Marchini, S
肿瘤
肿瘤免疫
卵巢癌
发表日期：2026
文献求助 收藏

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib

HR-SC 是一个学术界开发的机器学习框架，用于对 HRD 阳性卵巢癌患者进行分类并预测其对奥拉帕尼的敏感性。

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105060
Beltrame, L; Mannarino, L; Sergi, A; Velle, A; Treilleux, I; Pignata, S; Paracchini, L; Harter, P; Scambia, G; Perrone, F; González-Martin, A; Berger, R; Arenare, L; Hietanen, S; Califano, D; Derio, S; Van Gorp, T; Dalessandro, M L; Fujiwara, K; Provansal, M; Lorusso, D; Buderath, P; Masseroli, M; Ray-Coquard, I; Pujade-Lauraine, E; Romualdi, C; D'Incalci, M; Marchini, S
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

INOVATYON/ENGOT-ov5 研究：一项随机 III 期国际研究，比较曲贝替定/聚乙二醇化脂质体阿霉素 (PLD) 序贯铂类化疗与卡铂/PLD 方案治疗复发性卵巢癌（末次铂类化疗后 6-12 个月内进展）患者的疗效。

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-022-02108-7
Colombo, N; Gadducci, A; Sehouli, J; Rulli, E; Mäenpää, J; Sessa, C; Montes, A; Ottevanger, N B; Berger, R; Vergote, I; D'Incalci, M; Churruca Galaz, C; Chekerov, R; Nyvang, G B; Riniker, S; Herbertson, R; Fossati, R; Barretina-Ginesta, M P; Deryal, M; Mirza, M R; Biagioli, E; Iglesias, M; Funari, G; Romeo, M; Tasca, G; Pardo, B; Tognon, G; Rubio-Pérez, M J; DeCensi, A; De Giorgi, U; Zola, P; Benedetti Panici, P; Aglietta, M; Arcangeli, V; Zamagni, C; Bologna, A; Westermann, A; Heinzelmann-Schwarz, V; Tsibulak, I; Wimberger, P; Poveda, A
肿瘤
ENG
肿瘤免疫
卵巢癌
发表日期：2023
文献求助 收藏

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

MITO16A/MaNGO-OV2 试验中检测卵巢癌同源重组缺陷的替代学术方法

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100585
Capoluongo, E D; Pellegrino, B; Arenare, L; Califano, D; Scambia, G; Beltrame, L; Serra, V; Scaglione, G L; Spina, A; Cecere, S C; De Cecio, R; Normanno, N; Colombo, N; Lorusso, D; Russo, D; Nardelli, C; D'Incalci, M; Llop-Guevara, A; Pisano, C; Baldassarre, G; Mezzanzanica, D; Artioli, G; Setaro, M; Tasca, G; Roma, C; Campanini, N; Cinieri, S; Sergi, A; Musolino, A; Perrone, F; Chiodini, P; Marchini, S; Pignata, S
肿瘤
肿瘤免疫
卵巢癌
发表日期：2022
文献求助 收藏

Corrigendum to 'COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)': [ESMO Open Volume 6, Issue 3, June 2021, 100165]

关于“COVID-19疫情严重影响意大利癌症研究：意大利癌症协会（SIC）的一项调查”的更正：[ESMO Open 第6卷，第3期，2021年6月，100165]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100243
Bianchi, F; Dama, E; Di Nicolantonio, F; Baldassarre, G; Guerriero, I; Torchiaro, E; Bruno, A; Blandino, G; Allavena, P; Chiarugi, P; Sozzi, G; D'Incalci, M; Normanno, N
SMO
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)

COVID-19疫情对意大利癌症研究造成了严重影响：意大利癌症协会（SIC）的一项调查

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100165
Bianchi, F; Dama, E; Di Nicolantonio, F; Baldassarre, G; Guerriero, I; Torchiaro, E; Bruno, A; Blandino, G; Allavena, P; Chiarugi, P; Sozzi, G; D'Incalci, M; Normanno, N
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia

采用系统生物学方法研究曲贝替定在骨髓单核细胞白血病模型中的作用机制

期刊:Pharmacogenomics Journal
影响因子:2.9
doi:10.1038/tpj.2016.76
Mannarino, L; Paracchini, L; Craparotta, I; Romano, M; Marchini, S; Gatta, R; Erba, E; Clivio, L; Romualdi, C; D'Incalci, M; Beltrame, L; Pattini, L
白血病
细胞生物学
单核细胞
发表日期：2018
文献求助 收藏

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

曲贝替定在促纤维增生性小圆细胞肿瘤细胞中的作用机制

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-017-3091-1
Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini C M, D'Incalci M, Gatta R
肿瘤
发表日期：2017
文献求助 收藏

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

曲贝替定序贯伊立替康可稳定晚期易位阳性肉瘤的病情，且毒性可接受。

期刊:Sarcoma
影响因子:
doi:10.1155/2016/7461783
Herzog, J; von Klot-Heydenfeldt, F; Jabar, S; Ranft, A; Rossig, C; Dirksen, U; Van den Brande, J; D'Incalci, M; von Luettichau, I; Grohar, P J; Berdel, W E; Burdach, St
毒理研究
发表日期：2016
文献求助 收藏

Antiangiogenic activity of aplidine, a new agent of marine origin

一种源自海洋的新型抗血管生成剂——阿普利定的抗血管生成活性

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6601864
Taraboletti, G; Poli, M; Dossi, R; Manenti, L; Borsotti, P; Faircloth, G T; Broggini, M; D'Incalci, M; Ribatti, D; Giavazzi, R
血管生成
发表日期：2004
文献求助 收藏